Literature DB >> 1985428

Intellectual development in 12-year-old children treated for phenylketonuria.

C G Azen1, R Koch, E G Friedman, S Berlow, J Coldwell, W Krause, R Matalon, E McCabe, M O'Flynn, R Peterson.   

Abstract

Intelligence and achievement test scores were evaluated for 95 12-year-old children with phenylketonuria who had begun dietary therapy during the neonatal period. Dietary control of blood phenylalanine below 900 mumol/L was maintained beyond age 10 years in 23 children; 72 others had blood phenylalanine persistently above that level at ages ranging from 18 months to 10 years. Test scores at age 12 years were negatively correlated with the age at initiation of diet and with blood phenylalanine levels from ages 4 to 10 years, and positively correlated with parent IQ scores and the age at loss of dietary control. Children who maintained phenylalanine levels below 900 mumol/L beyond age 10 years showed no deficits in test scores, except for arithmetic, the scores of which declined between ages 6 and 12 years in 90% of the children in this study. These data strongly support a recommendation that dietary restriction of phenylalanine should be maintained through adolescence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985428     DOI: 10.1001/archpedi.1991.02160010037012

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  46 in total

Review 1.  Phenylketonuria: old disease, new approach to treatment.

Authors:  H L Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).

Authors:  Kelly J Hamman; Shelley R Winn; Cary O Harding
Journal:  Mol Genet Metab       Date:  2011-08-04       Impact factor: 4.797

3.  Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials.

Authors:  A P Prince; M P McMurray; N R Buist
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

4.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

5.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.

Authors:  Cary O Harding
Journal:  Biologics       Date:  2010-08-09

6.  Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study.

Authors:  F Rey; V Abadie; F Plainguet; J Rey
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria.

Authors:  P Burgard; E Schmidt; A Rupp; W Schneider; H J Bremer
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  Intelligence and professional career in young adults treated early for phenylketonuria.

Authors:  H Schmidt; P Burgard; J Pietz; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Summary of findings from the United States Collaborative Study of children treated for phenylketonuria.

Authors:  C Azen; R Koch; E Friedman; E Wenz; K Fishler
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Care of the adult with phenylketonuria.

Authors:  R Koch; C Azen; E G Friedman; K Fishler; C Baumann-Frischling; T Lin
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.